- $11.45bn
- $9.33bn
- $4.24bn
- 92
- 23
- 50
- 55
Annual income statement for Incyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,667 | 2,986 | 3,395 | 3,696 | 4,241 |
| Cost of Revenue | |||||
| Gross Profit | 2,557 | 2,857 | 3,209 | 3,463 | 3,953 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2,930 | 2,400 | 2,815 | 3,075 | 4,180 |
| Operating Profit | -264 | 586 | 579 | 621 | 61.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -232 | 570 | 529 | 834 | 317 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -296 | 949 | 341 | 598 | 32.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -296 | 949 | 341 | 598 | 32.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -296 | 949 | 341 | 598 | 32.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.16 | 4.42 | 1.58 | 2.74 | 0.31 |